Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding 'Board Comments on fine levied by the Exchange'.
AAREYDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarey Drugs & Pharmaceuticals informed the exchanges that both BSE and NSE levied a fine of ₹5,000 plus 18% GST (₹5,900 per exchange) for delayed submission of related party transaction disclosures required under Regulation 23(9) of SEBI LODR Regulations for the half-year ended September 30, 2025. The Board acknowledged the non-compliance and described the delay as inadvertent and procedural in nature. The required disclosure has since been submitted, and the total fine of ₹5,900 has been paid to each of the two exchanges. The Board has committed to strengthening internal compliance monitoring to avoid any repeat of such lapses.
The fine amount is small (₹5,900 per exchange) and has already been paid, so the direct financial impact on shareholders is negligible. However, repeated non-compliance with disclosure norms could attract stricter penalties, including potential freezing of promoter shareholdings or transfer to the Z group, so investors should watch for any future compliance lapses.